Cidara Therapeutics, Inc.
CDTX
Classifica tra le azioni
#3187
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Prezzo delle azioni
$221.38
Ultima sincronizzazione: 2026-01-08
Capitalizzazione di mercato
$5.61B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
118.07%
Paese
US
Scambia Cidara Therapeutics, Inc. (CDTX)
Categoria
Healthcare
Utile per Cidara Therapeutics, Inc. (CDTX)
Utile nel Sep 2025 TTM: $-184.80M
Secondo gli ultimi rapporti finanziari di Cidara Therapeutics, Inc., gli utili attuali della società sono $-184.80M. Nel 2023, la società ha registrato un utile di $-25.07M, un aumento rispetto a agli utili del 2022, che erano di $-33.31M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Cidara Therapeutics, Inc. dal 2012 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-184.80M | 8.52% |
| 2024 | $-170.29M | 579.40% |
| 2023 | $-25.07M | -24.76% |
| 2022 | $-33.31M | -21.56% |
| 2021 | $-42.47M | -41.11% |
| 2020 | $-72.11M | 75.49% |
| 2019 | $-41.09M | -30.37% |
| 2018 | $-59.02M | 5.90% |
| 2017 | $-55.73M | 15.70% |
| 2016 | $-48.17M | 49.61% |
| 2015 | $-32.19M | 170.67% |
| 2014 | $-11.89M | 784.97% |
| 2013 | $-1.34M | 69.70% |
| 2012 | $-792.00K | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -2,954.38% |
US
|
|
| $-3.09B | 1,570.45% |
US
|
|
| $-4.02B | 2,073.27% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,155.55% |
NL
|
